Jonathan Thomas Crocker, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hospitalists | 7 | 2021 | 304 | 1.360 |
Why?
|
| Faculty | 1 | 2022 | 383 | 0.680 |
Why?
|
| Clinical Competence | 6 | 2021 | 4681 | 0.440 |
Why?
|
| Relief Work | 1 | 2011 | 137 | 0.340 |
Why?
|
| Earthquakes | 1 | 2011 | 179 | 0.320 |
Why?
|
| Disaster Planning | 1 | 2011 | 549 | 0.250 |
Why?
|
| Physician's Role | 1 | 2011 | 942 | 0.230 |
Why?
|
| Internship and Residency | 1 | 2022 | 5774 | 0.210 |
Why?
|
| Translating | 1 | 2022 | 143 | 0.200 |
Why?
|
| Program Development | 2 | 2017 | 1314 | 0.190 |
Why?
|
| Credentialing | 1 | 2019 | 126 | 0.160 |
Why?
|
| Stavudine | 1 | 2015 | 85 | 0.130 |
Why?
|
| Teaching | 1 | 2022 | 1174 | 0.120 |
Why?
|
| Nevirapine | 1 | 2015 | 267 | 0.120 |
Why?
|
| Faculty, Medical | 1 | 2022 | 1182 | 0.120 |
Why?
|
| Lamivudine | 1 | 2015 | 342 | 0.120 |
Why?
|
| Curriculum | 4 | 2019 | 3589 | 0.110 |
Why?
|
| Sarcoma, Kaposi | 1 | 2015 | 370 | 0.100 |
Why?
|
| Telephone | 1 | 2012 | 617 | 0.080 |
Why?
|
| Hemangiopericytoma | 1 | 2009 | 77 | 0.080 |
Why?
|
| Haiti | 1 | 2011 | 551 | 0.080 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2009 | 271 | 0.080 |
Why?
|
| Communication | 2 | 2022 | 3728 | 0.080 |
Why?
|
| Genomic Imprinting | 1 | 2009 | 331 | 0.070 |
Why?
|
| Delivery of Health Care | 4 | 2017 | 5304 | 0.070 |
Why?
|
| Splenic Neoplasms | 1 | 2005 | 100 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 3611 | 0.060 |
Why?
|
| Hospitals | 4 | 2017 | 3937 | 0.060 |
Why?
|
| Dermatomyositis | 1 | 2005 | 223 | 0.060 |
Why?
|
| Hypoglycemia | 1 | 2009 | 859 | 0.050 |
Why?
|
| Education, Medical | 3 | 2017 | 1717 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2012 | 3300 | 0.040 |
Why?
|
| Spleen | 1 | 2005 | 2359 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 930 | 0.040 |
Why?
|
| Humans | 13 | 2022 | 742088 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 5867 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2012 | 3738 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2012 | 4551 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 1377 | 0.030 |
Why?
|
| Malawi | 1 | 2015 | 281 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2022 | 2680 | 0.030 |
Why?
|
| United States | 2 | 2019 | 69693 | 0.030 |
Why?
|
| Language | 1 | 2022 | 1458 | 0.030 |
Why?
|
| Documentation | 1 | 2017 | 865 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 5662 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2022 | 3215 | 0.020 |
Why?
|
| HIV Infections | 1 | 2015 | 16678 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2021 | 40450 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2009 | 454 | 0.020 |
Why?
|
| Rural Population | 1 | 2015 | 2207 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2005 | 440 | 0.010 |
Why?
|
| Muscle Weakness | 1 | 2005 | 414 | 0.010 |
Why?
|
| Fetus | 1 | 2009 | 1879 | 0.010 |
Why?
|
| Edema | 1 | 2005 | 790 | 0.010 |
Why?
|
| Exanthema | 1 | 2005 | 488 | 0.010 |
Why?
|
| Eye Diseases | 1 | 2005 | 670 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2009 | 4211 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 4839 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2012 | 3111 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 53187 | 0.010 |
Why?
|
| Research Design | 1 | 2012 | 5979 | 0.010 |
Why?
|
| Radiography | 1 | 2005 | 7010 | 0.010 |
Why?
|
| Middle Aged | 2 | 2022 | 213127 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 8425 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 5978 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 4353 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4933 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 12958 | 0.010 |
Why?
|
| Aged | 2 | 2017 | 162944 | 0.010 |
Why?
|
| Male | 3 | 2015 | 349538 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2015 | 77098 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2012 | 62966 | 0.000 |
Why?
|
| Adult | 1 | 2015 | 213712 | 0.000 |
Why?
|
| Female | 1 | 2015 | 379592 | 0.000 |
Why?
|